Amgen assisted the Pharmaceutical Research and Manufacturers of America (PhRMA) with the development of PhRMA's voluntary program to report counterfeit drugs to the FDA. Amgen participates in the program, designed to assist the FDA in carrying out its responsibilities to protect the public's health by removing counterfeit drugs from the marketplace. Upon receipt of credible information concerning distribution of any counterfeit Amgen product, Amgen will inform the FDA in an effort to further help the agency take swift enforcement action.